Glasdegib, an inhibitor of the Hedgehog pathway, targets the Smoothened protein, a transmembrane protein that mediates Hedgehog signaling, gained its approval in association with low-dose cytarabine (LDAC) in ND AML patients over 75 years old who are not eligible for ICT due to age or significant health issues [138]. This evidence concerns the gene SMO and acute myeloid leukemia.